Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press March 20, 2012, 4:59AM ET

AstraZeneca, Targacept end work on depression drug

Drug makers AstraZeneca and Targacept say they have abandoned plans to seek regulatory approval for a drug intended to treat major depressive disorder.

AstraZeneca PLC said Tuesday that the drug TC-5214 did not perform as hoped in an eight-week trial compared to a placebo.

AstraZeneca says it will take an impairment charge of $50 million as a result. The company's shares were down half a percent at 2,843.5 pence in London.

London-based AstraZeneca and Targacept Inc., based in Winston-Salem, North Carolina, signed a collaboration agreement to develop the drug in 2009.

BW Mall - Sponsored Links

Buy a link now!